Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW to Conduct Supply Chain Survey for Key Drugs
December 1, 2021
- LDP Pharma Study Group Urges 2% Adjustment Rate Plus Certain Range for 2022 Price Revision
December 1, 2021
- Japan Confirms 1st Case of Omicron Variant: MHLW
December 1, 2021
- MHLW Plans March Listing for “Off-Year” 2023
November 30, 2021
- Alzheimer’s Drugs in Mind, MHLW to Float New Rule for Potential Super Big Sellers
November 30, 2021
- 227 Billion Yen for Dual Use Manufacturing Facilities: FY2021 METI Extra Budget
November 29, 2021
- MHLW Earmarks 608 Billion Yen for COVID-19 Drug Initiatives: FY2021 Extra Budget
November 29, 2021
- Idorsia’s Cerebral Vasospasm Drug, Efient Label Expansion Clear PAFSC
November 29, 2021
- PMDA Reviewing Safety Risk of Imusera/Gilenya
November 29, 2021
- Olumiant Gets Sakigake Tag for Type I IFN Autoinflammatory Diseases
November 29, 2021
- PMDA Plans to Cut Review Fees for Fertility Treatments in January
November 26, 2021
- Japan Approves Jardiance for Heart Failure, Label Expansions for Opdivo and Keytruda
November 26, 2021
- Verify Adjustment Rate, Review Pricing Rule with Cost-Benefit Standpoint: CEFP
November 26, 2021
- Pharma Pushes 2% Adjustment Rate Plus Certain Range in 2022 Drug Price Revision
November 26, 2021
- Sanofi’s Praluent to Be Taken Off Japan NHI Price List Next Spring
November 26, 2021
- Medical Fee, Drug Price Revisions Major Topics for FY2022 Budget: MHLW
November 25, 2021
- LDP Health Panel Chief Vows to Push Development of Japan-Made Vaccines and Drugs
November 25, 2021
- 1st Lucentis Biosimilar, 3rd Humira Follow-On Get Japan Listing
November 24, 2021
- BMS’ Second CAR-T Therapy Ide-Cel Up for PAFSC Review on Dec. 6
November 24, 2021
- Orphan Status Granted to Daiichi Sankyo’s Valemetostat Tosilate, 2 Other APIs
November 24, 2021
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…